	US 12,280,094 B2
	Methods and compositions for natural killer cells
Alicja Copik, Casselberry, FL (US); Vijay Reddy, Orlando, FL (US); and Jeremiah Oyer, Longwood, FL (US)
Assigned to University of Central Florida Research Foundation, Inc., Orlando, FL (US)
Filed by UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., Orlando, FL (US)
Filed on Mar. 8, 2023, as Appl. No. 18/118,941.
Application 16/672,949 is a division of application No. 15/489,460, filed on Apr. 17, 2017, granted, now 10,463,715, issued on Nov. 5, 2019.
Application 18/118,941 is a continuation of application No. 16/672,949, filed on Nov. 4, 2019, granted, now 11,617,781.
Application 15/489,460 is a continuation of application No. 14/410,787, granted, now 9,623,082, issued on Apr. 18, 2017, previously published as PCT/US2013/048678, filed on Jun. 28, 2013.
Claims priority of provisional application 61/665,591, filed on Jun. 28, 2012.
Prior Publication US 2023/0321191 A1, Oct. 12, 2023
Int. Cl. C12N 5/0783 (2010.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01)

CPC A61K 38/20 (2013.01) [A61K 38/17 (2013.01); A61K 39/4613 (2023.05); A61K 39/464499 (2023.05); C12N 5/0646 (2013.01); A61K 2239/48 (2023.05); C12N 2500/84 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/50 (2013.01); C12N 2501/599 (2013.01)]

10 Claims

1. A pharmaceutical composition comprising:

an expanded population of NK cells, and

a pharmaceutically acceptable carrier,

the population of expanded NK cells having been exposed in vitro to an NK cell expanding composition free of feeder cells and comprising plasma membrane vesicles comprising at least one membrane-bound IL-21 and membrane bound 41BBL, wherein the plasma membrane vesicles are purified from NK cell feeder cells transfected with nucleic acid encoding the membrane-bound IL-21 and membrane-bound 41BBL, and, wherein the NK cell feeder cells comprise irradiated autologous or allogeneic peripheral blood mononuclear cells (PBMCs), RPMI8866, HFWT, K562 cells, or EBV-LCL.